🇺🇸 antiviral therapy in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Bronchopneumonia — 1 report (10%)
- Cd4 Lymphocytes Decreased — 1 report (10%)
- Cytomegalovirus Colitis — 1 report (10%)
- Diarrhoea — 1 report (10%)
- Disseminated Cytomegaloviral Infection — 1 report (10%)
- Drug Ineffective — 1 report (10%)
- Hepatic Failure — 1 report (10%)
- Hepatitis — 1 report (10%)
- Hypokalaemia — 1 report (10%)
- Pneumonitis — 1 report (10%)
antiviral therapy in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in United States
Frequently asked questions
Is antiviral therapy approved in United States?
antiviral therapy does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for antiviral therapy in United States?
National Taiwan University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.